Michael A Caligiuri

USPTO Granted Patents = 10 (Patent Applications = 27)

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 2 (Patent Applications = 10)

Average Co-Inventor Count = 2.9

ph-index = 3

Forward Citations = 54(Granted Patents)

Company Filing History:

6 out of 1,506

The Ohio State University

patents

2 out of 310

Health Research, Inc.

patents

2 out of 2

Cytoimmune Therapeutics, Inc.

patents

4. 1 out of 349

Arch Development Corporation

patents

where one patent can have more than one assignee

Years Active: 2000-2022

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11459378 - Passive antibody dependent cell-mediated activation (2022-10-04),

2. 11045543 - EGFR-directed car therapy for glioblastoma (2021-06-29),

3. 10973914 - Bivalent antibody directed against NKG2D and tumor associated antigens (2021-04-13),

4. 10961312 - FLT3 directed car cells for immunotherapy (2021-03-30),

5. 10167311 - Boronic acid esters and pharmaceutical formulations thereof (2019-01-01),

6. 9603873 - Activation of innate immunity by miRNA for cancer and infection treatment (2017-03-28),

7. 8530187 - Methods for transfecting natural killer cells (2013-09-10),

8. 7915043 - CD34(+) cells and their methods of use (2011-03-29),

9. 7306801 - Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein (2007-12-11),

10. 6042826 - Method for inducing apoptosis of primary central nervous system B cell (2000-03-28),

Title: Michael A Caligiuri: Innovator in Cancer Treatment and Immunology

Introduction

Michael A Caligiuri is a prominent inventor based in Columbus, OH (US), known for his significant contributions to the fields of immunology and cancer treatment. With a total of 10 patents, Caligiuri has developed innovative methods that enhance the efficacy of therapies for various diseases, particularly cancer.

Latest Patents

Among his latest patents, Caligiuri has introduced groundbreaking methods for treating subjects infected with pathogens. One notable patent describes a method of administering a pharmaceutical composition comprising an Fc region of an immunoglobulin G antibody to treat infections. Additionally, he has developed a method for treating cancer in subjects undergoing oncolytic viral therapy, which also utilizes the Fc region of an immunoglobulin G antibody. Another significant patent focuses on activating natural killer (NK) cells in infected subjects through similar pharmaceutical compositions. Furthermore, his work on EGFR-directed CAR therapy for glioblastoma addresses the challenges posed by aggressive brain malignancies, presenting compositions and methods for using CAR-expressing cells in treating various cancers, including glioblastoma and breast cancer brain metastases.

Career Highlights

Caligiuri has worked with notable organizations such as the Ohio State Innovation Foundation and Health Research, Inc. His career reflects a commitment to advancing medical science and improving patient outcomes through innovative research and development.

Collaborations

Throughout his career, Caligiuri has collaborated with esteemed colleagues, including Jianhua Yu and Neal J Meropol. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Michael A Caligiuri stands out as a key figure in the innovation of cancer therapies and immunological treatments. His patents and collaborative efforts continue to pave the way for advancements in medical science, ultimately benefiting patients worldwide.

This text is generated by artificial intelligence and may not be accurate.